Literature DB >> 6690409

Immunostimulation by Legionella pneumophila antigen preparations in vivo and in vitro.

H Friedman, R Widen, T Klein, W Johnson.   

Abstract

Injection of Legionella pneumophila antigen, either killed vaccine or soluble sonicate thereof, resulted in an enhanced antibody response by mouse spleen cells to sheep erythrocytes as determined by the hemolytic plaque assay. Enhancement was dose dependent and reached a peak response at a concentration of 10(7) bacteria or 50 micrograms of sonicate per animal. Larger doses of antigen were less stimulatory or even depressed the antibody response. Similar enhancement of antibody formation by normal spleen cell cultures to sheep erythrocytes in vitro occurred in the presence of graded amounts of L. pneumophila vaccine or sonicate. In addition, the L. pneumophila antigen stimulated enhanced background antibody formation in vitro in the absence of sheep erythrocytes or specific antigen. It appeared likely that the immunoenhancing activity of the L. pneumophila extract may be unrelated to the presence of lipopolysaccharide since boiling the antigen preparation eliminated much of the antibody-enhancing properties of the extract. A large-molecular-weight surface component from L. pneumophila was also immunomodulatory in vitro. Immunostimulation appeared to be related to effects on macrophages since adherent spleen cell populations rich in macrophages, when derived from spleen cell suspensions incubated with L. pneumophila antigen in vitro, stimulated enhanced antibody formation by normal mouse spleen cells in coculture experiments. Further investigations concerning the mechanism of immunomodulation by L. pneumophila antigen in vivo and in vitro appear to be warranted.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6690409      PMCID: PMC263433          DOI: 10.1128/iai.43.1.347-352.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  8 in total

1.  A simplified procedure for in vitro immunization of dispersed spleen cell cultures.

Authors:  I Kamo; S H Pan; H Friedman
Journal:  J Immunol Methods       Date:  1976       Impact factor: 2.303

2.  Immunological and biochemical relationships among flagella isolated from Legionella pneumophila serogroups 1, 2, and 3.

Authors:  J A Elliott; W Johnson
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

3.  Demonstration of the agent of Legionnaires' disease in tissue.

Authors:  F W Chandler; M D Hicklin; J A Blackmon
Journal:  N Engl J Med       Date:  1977-12-01       Impact factor: 91.245

4.  Legionnaires' disease bacterium (Legionella pneumophila) multiples intracellularly in human monocytes.

Authors:  M A Horwitz; S C Silverstein
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

5.  A high molecular weight antigen in Legionnaires' disease bacterium: isolation and partial characterization.

Authors:  W Johnson; J A Elliott; C M Helms; E D Renner
Journal:  Ann Intern Med       Date:  1979-04       Impact factor: 25.391

6.  "Endotoxicity" of the Legionnaires' disease bacterium.

Authors:  K H Wong; C W Moss; D H Hochstein; R J Arko; W O Schalla
Journal:  Ann Intern Med       Date:  1979-04       Impact factor: 25.391

7.  Role of antibody response helper factors in immunosuppressive effects of friend leukemia virus.

Authors:  R C Butler; J M Frier; M S Chapekar; M O Graham; H Friedman
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

8.  Cellular immunity to Legionella pneumophila in guinea pigs assessed by direct and indirect migration inhibition reactions in vitro.

Authors:  H Friedman; R Widen; I Lee; T Klein
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

  8 in total
  1 in total

1.  Kinetics and characterization of interferon production by murine spleen cells stimulated with Legionella pneumophila antigens.

Authors:  D K Blanchard; T W Klein; H Friedman; W E Stewart
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.